Pain Study Using Intermittent Bupivacain Injections After Breast Reconstruction With DIEP Flap
- Registration Number
- NCT00804674
- Lead Sponsor
- Ullevaal University Hospital
- Brief Summary
patients are given bupivacain intermittent locally on the donor site after brest reconstruction with diep flap. The hypothesis was that this approach will reduce the need for rescue analgetic medication and pain perception within the three first days
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 47
Inclusion Criteria
- all patients planned to undergo reconstructive breast surgery with a DIEP
Exclusion Criteria
- regular use of analgesics
- known allergic reaction to bupivacain
- bleeding disorders
- pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 placebo placebo - 1 bupivacain bupivacain -
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bupivacaine's analgesic effects at the donor site post-DIEP flap surgery?
How does intermittent bupivacaine compare to continuous infusion for postoperative pain management in breast reconstruction?
Are there specific biomarkers that predict response to bupivacaine infiltration after DIEP flap procedures?
What are the potential adverse events associated with repeated bupivacaine injections in abdominal donor sites?
How does bupivacaine compare to other local anesthetics like ropivacaine in reducing post-DIEP flap analgesic requirements?